JP2025507836A - 骨髄コンディショニング方法 - Google Patents

骨髄コンディショニング方法 Download PDF

Info

Publication number
JP2025507836A
JP2025507836A JP2024551941A JP2024551941A JP2025507836A JP 2025507836 A JP2025507836 A JP 2025507836A JP 2024551941 A JP2024551941 A JP 2024551941A JP 2024551941 A JP2024551941 A JP 2024551941A JP 2025507836 A JP2025507836 A JP 2025507836A
Authority
JP
Japan
Prior art keywords
seq
set forth
sequence set
antibody
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024551941A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025507836A5 (https=
Inventor
コン・パヌーシス
ヴェロニカ・レイズマン
Original Assignee
シーエスエル・イノベーション・プロプライエタリー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2022900484A external-priority patent/AU2022900484A0/en
Application filed by シーエスエル・イノベーション・プロプライエタリー・リミテッド filed Critical シーエスエル・イノベーション・プロプライエタリー・リミテッド
Publication of JP2025507836A publication Critical patent/JP2025507836A/ja
Publication of JP2025507836A5 publication Critical patent/JP2025507836A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2024551941A 2022-03-01 2023-03-01 骨髄コンディショニング方法 Pending JP2025507836A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2022900484A AU2022900484A0 (en) 2022-03-01 Methods of Bone Marrow Conditioning
AU2022900484 2022-03-01
PCT/AU2023/050138 WO2023164744A1 (en) 2022-03-01 2023-03-01 Methods of bone marrow conditioning

Publications (2)

Publication Number Publication Date
JP2025507836A true JP2025507836A (ja) 2025-03-21
JP2025507836A5 JP2025507836A5 (https=) 2026-03-09

Family

ID=87882677

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024551941A Pending JP2025507836A (ja) 2022-03-01 2023-03-01 骨髄コンディショニング方法

Country Status (6)

Country Link
US (1) US20250171536A1 (https=)
EP (1) EP4486784A1 (https=)
JP (1) JP2025507836A (https=)
CN (1) CN119156225A (https=)
AU (1) AU2023227214A1 (https=)
WO (1) WO2023164744A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026040957A1 (zh) * 2024-08-18 2026-02-26 尧唐(上海)生物科技有限公司 Cd117抗体及其应用
CN121537523B (zh) * 2026-01-19 2026-04-21 武汉睿欣和生物科技有限公司 一种用于胃蛋白酶原i检测的pgi单克隆抗体组合及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140212425A1 (en) * 2011-12-05 2014-07-31 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
EP4257145B1 (en) * 2014-08-26 2025-06-25 The Board of Trustees of the Leland Stanford Junior University Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling
GB201802201D0 (en) * 2018-02-09 2018-03-28 Ultrahuman Five Ltd Binding agents
US20200376135A1 (en) * 2018-10-23 2020-12-03 Magenta Therapeutics, Inc. Fc silenced antibody drug conjugates (adcs) and uses thereof
WO2020092655A1 (en) * 2018-10-30 2020-05-07 Magenta Therapeutics, Inc. Methods for allogeneic hematopoietic stem cell transplantation

Also Published As

Publication number Publication date
CN119156225A (zh) 2024-12-17
WO2023164744A1 (en) 2023-09-07
EP4486784A1 (en) 2025-01-08
AU2023227214A1 (en) 2024-10-10
US20250171536A1 (en) 2025-05-29

Similar Documents

Publication Publication Date Title
US10889652B2 (en) Antibodies and chimeric antigen receptors specific for ROR1
KR102294213B1 (ko) 항-cd38 항체
US10988543B2 (en) Humanized anti-tumor necrosis factor alpha receptor 2 (anti-TNFR2) antibodies and methods of use thereof to elicit an immune response against a tumor
JP6844719B2 (ja) 二重特異性抗体
US20230183344A1 (en) T-cell bispecific binding proteins
KR101822702B1 (ko) G-csfr에 대한 항체 및 이의 용도
KR20200133376A (ko) 신호-조절 단백질 알파에 대한 항체 및 사용 방법
US12612456B2 (en) CD19 antibodies and methods of using the same
CN113166243A (zh) 抗hla-g抗体、包含抗hla-g抗体的组合物和使用抗hla-g抗体的方法
TW201625686A (zh) 對ｃｄ１９具專一性之抗體及嵌合抗原受體
US20250171536A1 (en) Methods of Bone Marrow Conditioning
WO2022105811A1 (zh) Cd19人源化抗体及其应用
KR20230074192A (ko) 인간 cd3 엡실론에 결합하는 신규의 인간 항체
JP2024511642A (ja) 新規ｔｎｆｒ２結合分子
JP2026035723A (ja) 抗イヌｃｄ２０抗体
RU2814713C2 (ru) Биспецифическое антитело
JP7714992B2 (ja) 二重特異性抗体を有効成分として含む医薬組成物
RU2814713C9 (ru) Биспецифическое антитело
TW202606758A (zh) 抗cd74抗體組合物及方法
WO2025236034A1 (en) Anti-lma binding proteins
HK40042566A (en) Antibodies and chimeric antigen receptors specific for ror1
KR20240070579A (ko) 인간화 항-egfrviii 항체 및 이의 항원 결합 단편
HK1246314B (en) Antibodies and chimeric antigen receptors specific for ror1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260227